ImChristina Collins with CRWE Newswire Todays company highlight is ImmunoGen Incorporated – trading with the symbol IMGN —ImmunoGen Incorporated develops targeted anticancer therapeutics using the Companys expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers— The Companys Targeted Antibody Payload – TAP – technology uses monoclonal antibodies to deliver one of ImmunoGens proprietary cancer-cell killing agents specifically to tumor cells— There are currently six TAP compounds in clinical testing, with a wealth of clinical data reported with the technology — ImmunoGen recently reported that Bayer HealthCare Pharmaceuticals submission of an Investigational New Drug application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen— BAY 94-9343 is in development by Bayer HealthCare under an agreement with ImmunoGen that grants Bayer HealthCare exclusive rights to use the Companys maytansinoid TAP technology to develop anticancer therapeutics that target mesothelin— Mesothelin is highly expressed on mesotheliomas and on many ovarian and pancreatic carcinomas—In preclinical testing, BAY 94-9343 demonstrated potent, targeted anticancer activity against mesothelin-expressing tumors—Under this agreement, ImmunoGen is entitled to receive milestone payments potentially totaling up to $170.5 million for each resulting product plus royalties on sales— For more information about ImmunoGen <b>…<b>
**********************
MORE USEFUL INFORMATION....
The LINKS below are from high authority and related sites.
You might also find them useful. Thanks for visiting !
Targeted Antibody Payload
Targeted Antibody Payload
Clinical Center News
NIMH » Science News about Clinical Research and Trials
Recent Comments